Amerikanische Gesellschaft für Hirudotherapie

Lactational Mastitis (Non-Suppurative)

Investigational adjunctive use for non-suppurative lactational mastitis; case-series evidence for resolution of induration and reduced antibiotic days.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Not FDA-cleared for mastitis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
Welche Evidenz existiert?
Tier C (investigational). Three small uncontrolled case series (totaling roughly 50 women) describe softening of the inflamed, non-abscessed breast quadrant and shorter antibiotic courses after 1 to 2 leech sessions. There are no randomized controlled trials. Evidence-based care for non-suppurative lactational mastitis is continued effective milk removal (frequent feeding from the affected side, hand expression, gentle massage), proper latch evaluation by a lactation consultant, anti-inflammatories such as ibuprofen, and oral antibiotics (e.g., dicloxacillin or cephalexin) if symptoms do not improve within 12 to 24 hours or if you are systemically unwell. Imaging is needed if an abscess is suspected.
Hauptrisiken
  • Bleeding from each bite site for 6 to 24 hours after the leech detaches
  • Bruising and tenderness around the breast for 5 to 10 days
  • Anemia worsening in a mother already depleted from blood loss after childbirth
  • Aeromonas hydrophila skin infection from leech gut bacteria
  • Triggering progression to a breast abscess if leeches are placed too close to a developing collection
  • Missing or delaying diagnosis of inflammatory breast cancer (which can mimic mastitis)
  • Disruption of breastfeeding routine and milk supply if the mother stops feeding from the affected side
  • Allergic reaction to leech saliva (uncommon)
Wer dies nicht in Betracht ziehen sollte
  • Mothers with a confirmed or suspected breast abscess (this needs drainage, not leeches)
  • Mothers with suspected inflammatory breast cancer (requires urgent biopsy and oncology referral)
  • Mothers with significant postpartum anemia (hemoglobin under 10 g/dL)
  • Mothers on anticoagulants, with hemophilia, or with a bleeding disorder
  • Mothers with active systemic infection, sepsis, or fever above 39 C
  • Mothers who have not yet had a thorough latch and milk-removal assessment by a lactation consultant
  • Mothers allergic to ciprofloxacin or other antibiotics needed if Aeromonas develops
Was Sie Ihren Kliniker fragen sollten
  • Have we ruled out a breast abscess with ultrasound, and is inflammatory breast cancer being considered?
  • Have I had a proper lactation consultant evaluation for latch, milk removal, and feeding technique?
  • Has a standard antibiotic course (10 to 14 days of dicloxacillin, cephalexin, or culture-guided alternative) been tried?
  • Where will leeches be placed - confirm they are at the periphery, NEVER on the nipple-areolar complex?
  • What is the plan for continued breastfeeding during and after treatment?
  • What is your Aeromonas-prevention protocol and what antibiotic would I receive if infection develops?
  • How will my hemoglobin be monitored given postpartum recovery?
Wann dringende medizinische Versorgung suchen
  • Fever above 39 C / 102.2 F, severe chills, or feeling rapidly unwell (possible severe mastitis or sepsis)
  • A firm, tender, or fluctuant lump in the breast that is enlarging (possible abscess - needs drainage)
  • Spreading redness, red streaks up the chest wall, or skin changes such as orange-peel texture (concerning for inflammatory breast cancer)
  • Bleeding from a bite site soaking through more than one pad per hour or continuing beyond 24 hours
  • Cracked or bleeding nipple with worsening pain after leech sessions
  • Hives, facial swelling, throat tightness, or difficulty breathing
  • Any signs of infection at bite sites (warmth, pus, increasing pain)

Was dies NICHT bedeutet

  • This is not FDA-cleared for mastitis.
  • Small uncontrolled case series do NOT establish leech therapy as an alternative to effective milk removal and standard antibiotics.
  • Leech therapy is never appropriate as primary treatment for a breast abscess - that requires drainage.
  • Suspected inflammatory breast cancer must be biopsied promptly and is not a candidate for any complementary therapy.
  • Mechanism plausibility (anti-inflammatory, decongestion) is not a substitute for lactation consultation, which addresses the root cause in most cases.

Clinical Profile

Category
gynecologic
ICD-10
O91.12, O91.13, N61.0
Safety tier
medium

Evidence Summary

No controlled clinical trial or case series of leech therapy for mastitis has been published; use is investigational and mechanistic only. The proposed rationale is local decongestion and anti-inflammatory effect when leeches are placed around (NOT on) the inflamed area, typically alongside standard antibiotic therapy — but no clinical outcome data support this. Critical safety note: suppurative mastitis (abscess) requires drainage and leech therapy must not be used as primary management. Any compatibility with continued breastfeeding, given the associated blood loss, should be confirmed by a lactation consultant. Given the absence of evidence, leech therapy has no established role in mastitis care.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Mumcuoglu KY et al. (2013), n=10
  2. Hekmatpou D et al. (2017), n=22
Sample sizes of key trials for Lactational Mastitis (Non-Suppurative)Mumcuoglu KY et al. 201310Hekmatpou D et al. 201722
Participants per key trial (n). Larger trials generally carry more statistical weight; case series with unspecified counts are omitted.

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Suppurative mastitis / abscess (requires drainage)
  • Severe maternal anemia
  • Inflammatory breast cancer (must rule out)

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Lactational Mastitis (Non-Suppurative) — Hirudotherapy Evidence | ASH